We are contrasting ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC) and Oragenics Inc. (NYSEAMERICAN:OGEN) on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoCellular Therapeutics Ltd.	N/A	0.00	9.03M	-0.48	0.00
Oragenics Inc.	N/A	0.00	10.03M	-1.45	0.00

Demonstrates ImmunoCellular Therapeutics Ltd. and Oragenics Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows ImmunoCellular Therapeutics Ltd. and Oragenics Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
ImmunoCellular Therapeutics Ltd.	0.00%	-321.9%	-158.6%
Oragenics Inc.	0.00%	0%	-119.9%

Risk and Volatility

ImmunoCellular Therapeutics Ltd. has a beta of -0.31 and its 131.00% less volatile than S&P 500. Oragenics Inc. has a 1.03 beta and it is 3.00% more volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of ImmunoCellular Therapeutics Ltd. are 9.5 and 9.5. Competitively, Oragenics Inc. has 9.9 and 9.9 for Current and Quick Ratio. Oragenics Inc.’s better ability to pay short and long-term obligations than ImmunoCellular Therapeutics Ltd.

Institutional and Insider Ownership

Roughly 4.3% of ImmunoCellular Therapeutics Ltd. shares are held by institutional investors while 13.1% of Oragenics Inc. are owned by institutional investors. Insiders held 0.3% of ImmunoCellular Therapeutics Ltd. shares. Insiders Comparatively, held 1.1% of Oragenics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ImmunoCellular Therapeutics Ltd.	1.08%	-26.32%	-88.09%	-88.69%	-90.34%	-91.14%
Oragenics Inc.	-26.67%	-2.94%	135.6%	-34.43%	-69.16%	-57.85%

For the past year ImmunoCellular Therapeutics Ltd.’s stock price has bigger decline than Oragenics Inc.

Summary

Oragenics Inc. beats on 4 of the 6 factors ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has license agreement with Intrexon Corporation to use its technology to develop lantibiotics; and Intrexon Corporation and its wholly owned subsidiary, Actobiotics NV to use their intellectual property to develop AG013. It also has license agreement with LPThera LLC to develop LPT3-04 weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.